• All
  • Articles
  • Conferences
  • COVID-19
  • Miscellaneous
  • Research
  • Uncategorized

Fluidda interviewed in “Precision Medicine” issue Pharma Focus Asia

In the latest issue of the magazine Pharma Focus Asia, dedicated to precision medicine and personalizing health outcomes, the founders of Fluidda were interviewed. In this interview titled: “ Functional… View Article

Novel FRI parameter analyzing the pulmonary vascular bed accurately predicts outcomes in COVID-19 disease, and can be decisive in choice of therapy.

In a recent publication in the European Respiratory Journal (ERJ) by Morris et al. a retrospective analysis was performed of chest CT scans of 313 COVID-19 positive and 195 COVID-19 negative patients seeking acute medical care. From… View Article

Over 5000 COVID-19 patients already analyzed with Fluidda’s new blood vessel volume FRI parameter

We are pleased to announce that CT scans of more than 5000 COVID-19 patients from all corners of the world have been analyzed with Fluidda’s recently developed BVX parameter! The BVX parameter… View Article

Drug delivery and lung deposition using the Aerosphere™ inhaler, a study performed with FRI technology.

Metered dose inhalers (MDI’s) are one of the most common device types for delivering inhaled therapies. However, there are several technical challenges in development and drug delivery of these medications…. View Article

Fluidda joins P4O2 Consortium

Prevention is the key to healthy lungs.The quality of life for patients with chronic lung diseases like asthma, COPD, and lung cancer can- and should be improved. The Dutch consortium… View Article

Predicting Lung Deposition of extrafine ICS Containing Fixed Combinations COPD patients using FRI in an in silico study.

In a recent study by Usmani et al. , FRI was used to evaluate lung deposition of extrafine beclomethasone dipropionate (BDP)/formoterol fumarate (FF)/glycopyrronium bromide (GB) and extrafine BDP/FF delivered through pressurized metered… View Article

New FRI Article: Cluckers et al: Interstitial lung disease in systemic sclerosis

FRI is able to differentiate moderate to severe versus limited disease and to detect disease progression in systemic sclerosis. Systemic sclerosis–associated ILD accounts for up to 20% of mortality in these patients… View Article

TV News Show – January 14th – FRI in COVID-19 longhaulers

FRI on PBS news hour: Medical community scrambles to understand COVID-19 ‘long haulers’ During a news item on PBS news hour, January 13, COVID-19 “long haulers” were discussed. Long haulers are COVID-19 patients… View Article

Fluidda’s COVID-19 consortium

Today, one year into the COVID-19 pandemic, we live in a changed world. With over a million deaths and many millions suffering long-term disability as a result of lasting damage… View Article

Press release – Results PINTA trial Galapagos on IPF while using FRI

Galapagos Announces Positive Topline Results in Phase 2 Study Using FRI Imaging Parameters While Investigating New Medication for IPF Patients. The PINTA trial was a randomized, double-blind, placebo-controlled trial investigating… View Article

Visualisation FRI study – Effect lung deposition by adding an Aerochamber when using a pMDI in COPD

Evaluations of inhaler use have demonstrated that mishandling of pMDIs (Pressurized Meter Dose Inhalers) is commonplace. One of the most common errors is the failure to coordinate inhalation with actuation… View Article

FRI Biomarker Overview

The added value of FRI in treating lung diseases. Fluidda developed a large number of HRCT-derived imaging parameters, based on its proprietary Functional Respiratory Imaging (FRI) technique, to generate very… View Article

World COPD-Day 2020

The use of Fluidda’s FRI technology in the combat against COPD. The exact prevalence of COPD worldwide is largely unknown, but estimates have varied from 7-19%. The Burden of Obstructive Lung Disease (BOLD) study… View Article

BVX scans with COVID-patients – Delta Hospital

Delta Hospital uses new imaging technology for better triage and optimal treatment of COVID-19 patients. Due to the very large number of Corona patients who now report daily for hospitalization,… View Article

Poster CHEST 2020: AZ studie Maarten van den Berge

FRI assessment of a fixed Triple Therapy (Bud/Gly/FF) and a fixed Dual Therapy (Gly/FF) in patients with COPD In a study presented as a poster at the virtual Chest conference, FRI was used… View Article

FLUIDDA’s Online Site Training Course For Clinical Research Sites

Fluidda’s Online Site Training Course For Clinical Research Sites goes ” LIVE”  For years Fluidda educates pulmonologists and CT-scanning personnel “on site” how to perform HRCT-scans that can be used in Clinical Trials… View Article

The Perfect Storm

Time for a paradigm shift in lung function research? The golden age of pulmonary function testing began in the 1920s, driven by the increasing prevalence of occupational lung disease and resulting interest… View Article

Fluidda’s FRI-activities are at “Full Speed” during this COVID-19 pandemic

Fluidda’s FRI-activities are at “Full Speed” during this COVID-19 pandemic The COVID-19 crisis has had a tremendous impact on the initiation and progression of clinical research around the world and… View Article

P4O2 press release Netherlands Respiratory Society (NRS)

A Public-private consortium P4O2 (Precision Medicine for more Oxygen) investigates risk factors for developing lung damage and chronic complaints after COVID-19. Many patients who have had COVID-19 continue to have… View Article

Assessing short term effects of Orkambi on lung function in CF patients

FRI used to assess short-term effects of Orkambi on lung function in patients with CF homozygous for F508de The Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) modulator Orkambi (lumacaftor-ivacaftor) has shown modest benefits… View Article

Fluidda’s clinical research on COVID-19 in Belgian HCP-magazine.

On July 1, Chiesi and Fluidda organized an international webinar for pneumologists and other health professionals, discussing the use of Functional Respiratory Imaging during the covid-19 pandemic in three different… View Article

ERS 2020 – Lung Deposition of Two Bronchodilators in Subjects With COPD

Lung Deposition of Two Bronchodilators in Subjects with COPD When Administered via Standard Jet Nebulizer or HandiHaler® Using FRI. During the ERS Congress 2020, a poster was presented comparing lung deposition of… View Article

ERS 2020 – FRI shows significant regional ventilation defects in COPD

Functional Respiratory Imaging (FRI) shows significant regional ventilation defects in COPD patients as compared to healthy patients Ventilation defects in COPD are associated with reduced exercise tolerance and worse quality… View Article

ERS 2020 – Ventilation-perfusion measures based on FRI correlates with exercise tolerance and PRO’s in COPD

Ventilation-perfusion measures based on FRI correlates with exercise tolerance in COPD COPD affects the lungs in many ways. A common problem is reduced ventilation-perfusion (V/Q) values caused by airway disease… View Article

FRI identifies redistribution of pulmonary blood flow in patients with COVID-19

Functional respiratory imaging identifies changes in pulmonary blood flow in patients with COVID-19 An common observation is that some patients with COVID-19 have normal lung compliance but significant hypoxaemia different from… View Article

Use of FRI in deposition of inhaled lip. cyclosporin in BOS

Use Of Functional Respiratory Imaging (FRI) To Explore Drug Delivery And Lung Deposition Of Inhaled Liposomal Cyclosporine A (L-CsA-i) In Patients After Lung Transplantation (LTx) FRI-based biomarkers have been investigated as… View Article

Summer Holiday Card 2020

Webcast Mundipharma – July 15th 2020

On July 15, from 6 – 7.30 pm GMT, Mundipharma organizes a webinar for pulmonologists and other interested HCP’s on respiratory topics in the focus of interest, such as the… View Article

Podcast with Dr. Rola on the clinical possibilities of FRI

On July 3rd, Fluidda’s CEO Dr Jan De Backer had a podcast interview with Dr Philippe Rola, president of the critical care unit at the Santa Cabrini Hospital in Montreal,… View Article

Webinar – Lessons Learned from COVID-19 – Now Available Offline

This week a very high rated webinar was broadcast where the latest findings on COVID-19 research with FRI-technology was presented by prominent pulmonologists and radiologists from all over the world…. View Article

Webinar – Lessons learned from the COVID-19 crisis

Lessons learned from the COVID-19 crisis. This is the title of a webinar Fluidda and Chiesi will broadcast on July 1st at 8 pm CET for interested pulmonologists and other… View Article

Assessment of small pulmonary blood vessels in COVID-19 patients using HRCT

New publication on FRI: Assessment of small pulmonary blood vessels in COVID-19 patients using HRCT Mounting evidence supports the role of pulmonary hemodynamic alterations in the pathogenesis of COVID-19. Building… View Article

Comparison inhalation with pMDI and pMDI/spacer on drug delivery in the lung using FRI technology

Published in: Am J Respir Crit Care Med 2020;201:A5689 Authors: J. Suggett1, V. Kushnarev(1) , C. Van Holsbeke (2) , S. Van Steen(2) , B. Mignot(2) 1) Trudell Medical International, London,… View Article

Theoretical Model of the Pathophysiology of COVID-19 using FRI-data in EMCRIT podcast

During an EMCRIT podcast last week. Dr. Farid Jalali (Long beach CA) laid out a theoretical framework for the pathophysiology of the lung effects of COVID-19. Take Home Points from this podcast… View Article

FRI assessment of Glycopyrrolate and FF pMDIs using co-delivery technology in COPD

New published article: FRI assessment of glycopyrrolate and formoterol fumarate pMDI formulations using co-suspension delivery technology in COPD. Understanding lungs and lung diseases has never been more important than in… View Article

Effectiveness of a new mobile HFCWO device for airway clearance in CF patients

Fluidda studied the effectiveness of a new mobile HFCWO device for airway clearance in CF patients. High-frequency chest wall oscillation (HFCWO) is a commonly used airway clearance technique for cystic… View Article

Full Broadcast – Kathy Ireland Interview

Worldwide Business with Kathy Ireland® is an award-winning business and health program. The show provides its viewers with an in-depth opportunity to find solutions to industry problems from some of… View Article

COVID-19 – Kathy Ireland Interview

Worldwide Business with Kathy Ireland® is an award-winning business and health program. The show provides its viewers with an in-depth opportunity to find solutions to industry problems from some of… View Article

Diseases and Spirometry – Kathy Ireland Interview

Jan De Backer, Fluidda CEO, interviewed in USA television program: Worldwide Business with Kathy Ireland. (Part three) Worldwide Business with Kathy Ireland® is an award-winning business and health program. The show provides its… View Article

Interview Announcement

LIVE STREAM ANNOUNCEMENT: Fluidda’s CEO will be interviewed on USA television. Dr. Jan De Backer, Fluidda CEO, was recently interviewed about the company’s work on facilitating diagnosis and treatment of… View Article

Our consortium on COVID-19

LET’S TACKLE COVID-19 IN A CONSORTIUM! In an ongoing effort, Fluidda is collecting several batches of HRCT-scans of COVID19-patients to analyze them with their Functional Respiratory Imaging (FRI) technology in… View Article

What is FRI – Kathy Ireland Interview

Jan De Backer, Fluidda CEO, interviewed in USA television program Worldwide Business with Kathy Ireland. (Part two) Worldwide Business with Kathy Ireland® is an award-winning business and health program. The show provides its… View Article

Our mission and vision – Kathy Ireland Interview

Jan De Backer, Fluidda CEO, interviewed in USA television program Worldwide Business with Kathy Ireland. (Part one) Worldwide Business with Kathy Ireland® is an award-winning business and health program. The show provides its… View Article

Antwerp biotech company improves lung damage predictability using 3D scans.

By Pieter Haeck, reporter Belgian newspaper “De Tijd”.  April 7, 2020 What is the prognosis for someone infected with the corona virus? Will the patient deteriorate quickly or not? The… View Article

New 3D-printed connector for non-invasive ventilation developed by Materialise and Fluidda.

Materialise and Fluidda worked together in the development of a 3D-printed Non-Invasive PEEP Mask to Alleviate Ventilator Shortage For several years. Materialise, a Belgian 3D printing company with one of… View Article

Medtech goes to war with COVID-19 (DeviceTalks Weekly)

In the most recent Device Talk podcast, Jan de Backer, CEO of Fluidda, was interviewed about medtech’s essential role in the escalating war against COVID-19.  He explains how Fluidda’s proprietary… View Article

FDA clears Fluidda’s Broncholab platform for use in Clinical Practice

The US Food and Drug Administration provided market clearance to Fluidda for its Broncholab platform. Broncholab provides a number of Functional Respiratory Imaging (FRI) parameters to physicians via an online… View Article

Airway volume measurement with FRI identifies IPF progression

Idiopathic pulmonary fibrosis (IPF) is a progressive disease with unclear etiology. IPF patients decline with heterogeneous trajectories. The ability to determine an individual’s disease course is limited to pulmonary function measurement… View Article

Fluidda’s investigational network of FRI sites

Fluidda’s investigational FRI sites are located all over the world, enhancing clinical research with FRI locally. Fluidda is the world leader in the field of Functional Respiratory Imaging. This technique combines HRCT scans,… View Article

FDA – FRI acknowledged important tool for investigating deposition

In a recent article, the Food and Drug Administration (FDA) mentioned Fluidda’s FRI technology as an important tool to investigate regional drug deposition of the extrathoracic region, especially to measure… View Article

FRI may be able to help in optimizing lung tumor treatment

Functional Respiratory Imaging (FRI) may be able to help in optimizing lung tumor treatment. It is not enough to only look at nodule size as one parameter to determine treatment… View Article
Bronchial Thermoplasty - Image courtesy of Boston Scientific

Bronchial thermoplasty increases airway volume

In a recent study, 10 patients with unstable, severe asthma were treated with Bronchial Thermoplasty (BT) of the left lung, while the right lung was used as an internal control. Changes in… View Article

Effectiveness of a mobile HFCWO device for airway clearance

High Frequency Chest Wall Oscillation (HFCWO) is a commonly used airway clearance technique for Cystic Fibrosis (CF) patients. At ERS 2019 in Madrid, a poster was presented on this topic…. View Article

FiGHT Australian wildfires

Fluidda helps firefighters! Because of climate change, there is an increasing number of spontaneous wildfires all over the world, as we are now unfortunately experiencing in Australia. Fluidda, the company… View Article

The usage of AI in medical imaging

At the ERS 2019 conference in Madrid, our Director of Research and Development of Fluidda, gave his opinion on how Artificial Intelligence can help to improve the prediction of respiratory… View Article

Happy Holidays 2019 – 2020

Fluidda wishes you happy holidays and an inspiring 2020!
Maarten Lanclus' PhD on AI using FRI

PhD thesis on using AI in combination with FRI

At the University of Antwerp, Maarten Lanclus, Research & Development director of Fluidda, successfully defended his thesis on the topic of using Artificial Intelligence (A.I.) in combination with FRI to enhance… View Article

Our corporate responsibility project – ERS 2019

At ERS 2019, Cedric van Holsbeke, Chief Technology Officer of Fluidda talks about Fluidda’s corporate responsibility project. Laptops, previously used for patient training purposes and training of clinical sites, have been donated by… View Article

DDL Conference 11 – 13 December Edinburgh

The Drug Delivery to the Lungs (DDL) Conference provides an annual forum for scientists, academics, clinicians, regulatory and industry specialists involved in developing medicines for inhalation. Fluidda is actively involved in… View Article

The effects of particle size in deposition projects – ERS 2019

During the ERS 2019 two posters were presented on the deposition of extrafine vs. non-extrafine formulations of different respiratory drugs in different inhalation devices. Both studies were conducted with Functional… View Article

How does FRI compare to spirometry?

Functional Respiratory Imaging (FRI) parameters can reduce the number of patients required in clinical trials up to sixteen times compared with spirometry while maintaining adequate power and statistical significance. FRI… View Article
Professor De Backer

The value of Fluidda in respiratory clinical research – ERS 2019

Prof. W. De Backer, Chairman of the Board of Fluidda nv, was interviewed at the ERS 2019 conference in Madrid about the insights that lead to the founding of the… View Article

The advantages of using FRI in clinical trials – ERS 2019

Glenn Leemans, Fluidda’s Chief Operative Officer (COO), was interviewed at the ERS 2019 conference in Madrid. In this interview, Glenn explains why Fluidda’s proprietary functional respiratory imaging (FRI) technique can… View Article
RSNA 2019

RSNA 2019 – Annual Congress 1st – 6th December Chicago

Fluidda will be present at the annual congress of the Radiological Society of North America (RSNA). This year’s congress will take place during 1-6 December in Chicago, Illinois . The RSNA… View Article

Using FRI to detect early wildfire exposure on lung development

During the ERS 2019 conference, Fluidda presented the results of a study which investigated that FRI (Functional Respiratory Imaging) parameters can be a sensitive tool to detect early-life wildfire smoke… View Article
Mucus in COPD

Understanding Mucus in Chronic Obstructive Pulmonary Disease (COPD)

Mucus plays a major role in Chronic Obstructive Pulmonary Disease (COPD), especially in the Chronic Bronchitis phenotypes. Mucus increases airway resistance making it harder for the patient to breath. At… View Article

The highlights of ERS 2019 by Jan De Backer, CEO of Fluidda

At ERS 2019, Jan de Backer, CEO of Fluidda, explains why during the past years, the treatment of lung diseases is shifting from using more common bronchodilatators to more personalized… View Article

ERS 2019 – We are present with our booth and 7 posters

From September 28 until October 2, Fluidda will exhibit at the annual conference of the European Respiratory Society (ERS) in Madrid, Spain. During this conference, Fluidda will present 7 posters on… View Article

Fluidda will be present at the Annual Drug Discovery & Development Symposium on Pulmonary Vascular Disease

This year’s symposium will take place in Paris on July 1-2. Each year the meeting brings leading scientists in the fields of pulmonary vascular disease, right heart failure, and clinical trial… View Article

Fluidda attends the International Conference of Medical imaging with Deep Learning

During July 8-10 the International Conference of Medical imaging with Deep Learning takes place in London. The FLUIDDA team, specialised in using advanced A.I. algorithms to extract clinically relevant regional… View Article

Bronchial thermoplasty increases airway volume measured by Functional Respiratory Imaging (FRI)

In a recently published study (click here for full article) 10 patients with unstable, severe asthma were treated with bronchial thermoplasty of the left lung, while the right lung was used as an… View Article